Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.

ABSTRACT:

Background

Treatment options for patients with urothelial cancer (UC) refractory to platinum and immunotherapy are limited and survival is short. Enfortumab vedotin (EV) is a monoclonal anti-NECTIN4 antibody conjugated to monomethyl auristatin. It was recently approved because of superior survival in comparison to standard-of-care (SOC) chemotherapy. Real-world patients, however, often have worse characteristics than patients included in clinical trials.

Objective

To analyze the efficacy and safety of EV in a cohort of real-world patients.

Design setting and participants

Retrospective data were collected from 23 hospitals and private practices for patients with metastatic and previously treated UC who received EV either when reimbursed by their insurance company befor

SUBMITTER: Zschabitz S 

PROVIDER: S-EPMC10334227 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature